B&K CORP-B

B&K Corporation staged a sharp intraday reversal, opening lower but rallying in the afternoon session to close at HKD 4.300, up 5.65% from the previous close, with an intraday swing of 11.69% after hitting a 52-week low of HKD 3.850. The stock, which has plunged 88.44% from its 52-week high of HKD 37.2 and is down 73.16% YTD, remains below its 20-day (HKD 4.546) and 60-day (HKD 5.771) moving averages. The rebound was driven by news that the company enrolled its first patient in a Phase IIIa trial for a key burn treatment, alongside a 109.06% YoY revenue surge to approximately HKD 580,000 in Q4 2025, though its net loss widened to HKD 82.9 million. However, trading volume remained thin at 50,400 shares, with a turnover rate of just 0.06%.

华芢生物-B 今日低开探底后小幅回升，收盘报 4.05 港元，跌 0.7%，主要因公司基本面持续承压且股价仍处弱势区间。盘中最低触及 3.62 港元，逼近 52 周低点 3.61 港元，距 52 周高点 37.20 港元跌幅达 89.1%；YTD 累计跌 74.7%，均线系统呈空头排列（MA20 4.60/MA60 5.83）。财报显示 Q4 2025 营收同比增 109% 至 58 万港元，但净亏损扩大 61.8% 至 8286 万港元，每股亏损 0.81 港元，盈利能力未见改善。消息面上，针对烧伤的 IIIa 期临床已启动首例入组，全年股东大会通过治理及资本授权决议。不过，全日成交仅 6000 股、换手率 0.01%，显示缺乏资金关注。